Sign in
Taking people in United StatesPhase 4

Tests tirzepatide effects on muscle and bone during weight loss

Studies muscle and bone changes in adults with obesity taking tirzepatide for weight loss.

Key facts

Who runs it
Pennington Biomedical Research Center
Where
Baton Rouge and Scarborough, United StatesSee the 2 sites
Trial code
Registry title
GLP-1R Actions on Muscle and the Skeleton
Status
Recruiting
Phase
Phase 4
People taking part
50 people, planned
Started
9 Oct 2025
Expected to end
1 May 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Tirzepatide
  • Lifestyle toolkit
Record updated
27 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 50 with obesity, to study muscle and bone changes after weight loss with tirzepatide, with or without a diet and exercise program.

Age
18 to 50 years (inclusive).
Sex
Men and women. Women must be premenopausal.
Disease stage
Obesity with a BMI between 30 and 40 kg/m2 (inclusive).
Earlier treatment
People on steroid pills or other drugs that cause muscle and bone loss, on drugs that change weight, or on osteoporosis treatment cannot join.
Biomarker or test result
Vitamin D (25-OH) level must not be below 15 ng/ml.

Main reasons for not taking part

  • Known osteoporosis or osteoporosis treatment
  • Past cancer other than non-melanoma skin cancer
  • Diabetes, kidney disease, liver disease or a significant blood abnormality
  • Pregnancy, or menopause in women
  • Cannot have an MRI scan, or depression score (PHQ-9) of 15 or more

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Subjects will have a BMI between 30kg/m2; 40kg/m2 (inclusive)
  • Be between 18 and 50 years of age (inclusive)
  • Non-Hispanic Black males and females will be enrolled at PBRC
  • Rural males and females will be enrolled at MaineHealth
  • Female subjects will be premenopausal
  • Females have had their last menstrual period less than 60 days before screening
  • Females have the absence of menopausal-associated vasomotor symptoms
  • All subjects must be able to use Lifestyle Toolkit as prescribed for intervention arm

Who cannot take part

  • Subjects on systemic corticosteroids or other agents known to increase loss of muscle and bone mass
  • Subjects who are on medications that increase or decrease weight status
  • Subjects with known osteoporosis or are on osteoporosis therapies (gonadal hormones or hormone antagonists)
  • Females of childbearing potential who do not agree to using an effective method of contraception during the study. Medically acceptable methods include oral contraceptive medication, an intrauterine device (IUD), an implantable contraceptive (such as Implanon), or a barrier method (such as condom or diaphragm with spermicide); Injectable contraceptives such as Depo-Provera are a cause for exclusion in that they can cause bone loss; Abstinence is acceptable, as is sexual activity exclusively with same sex partners; Fertility Appreciation Based Methods (natural family planning) are also acceptable forms of addressing childbearing potential in all subjects. A urine pregnancy test (UPT) will be performed on all females of childbearing potential at the screening visit, 3 and 6 months
  • Contraindication to MRI - including but not limited to non-removable metallic or electronic implants, claustrophobia or other fear of confinement, inability to tolerate loud scanner noise, body weight greater than 500 pounds
  • Any significant EKG abnormalities that are considered a risk for utilizing weight management therapies
  • Subjects with a history of malignancy other than non-melanoma skin cancer
  • Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results
  • Subjects with a clinically significant hematologic abnormality, kidney disease, liver disease, or diabetes
  • Males and females over the age of 50 years of age
  • Menopausal females
  • Subjects having contraindications to tirzepatide in the package insert
  • Unable to follow Lifestyle Toolkit as prescribed for intervention arm
  • Patient Health Questionnaire-9 (PHQ-9) Score equal to or greater than 15 (clinical depression)
  • Adults who are unable to consent
  • Individuals who are not yet adults (infants, children and teenagers)
  • Pregnant females
  • Incarcerated individuals
  • Subjects with a baseline level of 25-OH vitamin D <15 ng/ml will be excluded from the trial. The subject's physician will be notified, and the subject will be referred to their primary care physician

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

Where in United States

  • Pennington Biomedical Research CenterBaton Rouge, United StatesContact: Adithya Hari, MDNo longer taking part
  • MaineHealth Center for Clinical and Translational ScienceScarborough, United StatesContact: Irwin Brodsky, MD, MPHTaking people

About the trial

What the trial wants to find out

The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.

The 2 groups in the trial

  • Treatment/intervention groupTreatment being tested

    Treatment with Tirzepatide for 5 months and lifestyle toolkit.

    Treatment: Tirzepatide

  • Control/PlaceboPlacebo, for comparison

    Treatment with Tirzepatide for 5 months with regular diet and exercise.

    Treatment: Lifestyle toolkit

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
GLP-1R Actions on Muscle and the Skeleton
Plain-language title
Tests tirzepatide effects on muscle and bone during weight lossGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07154719, who can take part
Record updated
27 August 2026